Gideon Schreiber, University of Toronto

Research

Cancer Immunotherapy Checkpoint Inhibitors Endocytosis Gene Expression Immunosuppression Janus Kinases Leukemia Lipids

Latest funding

Understanding the role of type 1 interferon in resistance to cancer immunotherapy
CIHR · 2017 · Principal investigator

Understanding the role of type 1 interferon in resistance to cancer immunotherapy

Principal investigatorCIHR2017Joint Canada-Israel Health Research Program

Principal investigators: Spaner, David E; Schreiber, Gideon

Keywords: Cancer Immunotherapy; Checkpoint Inhibitors; Endocytosis; Gene Expression; Immunosuppression; Janus Kinases; Leukemia; Lipids; Transgenic Mice; Type 1 Interferon

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Subject: Prospective PhD student: Cancer Immunotherapy Dear Professor Schreiber, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. Your research on cancer immunotherapy connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]